The 429 monoclonal antibody specifically binds to both the long (~110 kDa) transmembrane-spanning form and the truncated (~47 kDa) GPI-linked form of vascular cell adhesion molecule-1 (VCAM-1, CD106). CD106 is constitutively expressed on bone marrow stromal cells, myeloid cells, and splenic dendritic cells. Its expression on endothelial cells is upregulated by inflammatory cytokines and in certain pathologic conditions. CD106 expression has also been detected on apoptotic thymocytes, splenocytes, and lymphoid cell lines. VCAM-1 is a counter-receptor for VLA-4 (α4β1 integrin) and LPAM-1 (α4β7 integrin), and the 429 antibody partially blocks VCAM-1-mediated binding functions. Source of the immunogen was the mouse preadipose cell line PA6.
The antibody was conjugated to an oligonucleotide that contains an antibody clone-specific barcode (ABC) flanked by a poly-A tail on the 3' end and a PCR handle (PCR primer binding site) on the 5' end. The ABC for this antibody was designed to be used with other BD AbSeq oligonucleotides conjugated to other antibodies. All AbSeq ABC sequences were selected in silico to be unique from human and mouse genomes, have low predicted secondary structure, and have high Hamming distance within the BD AbSeq portfolio, to allow for sequencing error correction and unique mapping. The poly-A tail of the oligonucleotide allows the ABC to be captured by the BD Rhapsody™ system. The 5' PCR handle allows for efficient sequencing library generation for Illumina sequencing platforms.
NOTE: The BD Rhapsody Single-Cell Analysis System must be used with the BD Rhapsody Express Instrument.